Date: 2011-09-16
Type of information: R&D agreement
Compound:
Company: Scil Proteins (Germany) Martin Luther University Halle-Wittenberg (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: gastrointestinal tumors.
Details: Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, has signed a collaboration agreement with the Martin Luther University Halle-Wittenberg to research innovative therapies for gastrointestinal tumors. The project will be run by Professor Dr. Thomas Seufferlein, head of the University Hospital’s gastroenterology clinic, and will focus on the discovery and characterisation of disease-related molecular structures. Scil Proteins will then use the Company’s proprietary Affilin® platform to identify effective therapeutics and advance them into further clinical development.
Financial terms:
Latest news:
